Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
indiana blog main
7
×
indiana top stories
life sciences
national blog main
raleigh-durham blog main
7
×
raleigh-durham top stories
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
national
amgen
clinical trials
cancer
fda
diagnostics
eli lilly
europe blog main
europe top stories
hepatitis b
immunotherapy
medicaid
medicare
merck
What
drug
7
×
fda
new
approval
bio
friday
market
patients
plan
roundup
won
acquisitions
acute
addresses
advantages
agency
aimmune
allergy
anathema
approved
awaited
awarded
bar
biggest
brings
build
buy
cancer
causes
ceo
cholesterol
company’s
condition
daniel
debut
decades
democrat
details
developed
drugs
Language
unset
7
×
Current search:
drug
×
unset
×
" raleigh-durham blog main "
×
" indiana blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)